38175-35-8

Usage

Uses

Used in Pharmaceutical Industry:
3-(3-Methoxyphenyl)pyrrolidine is used as a precursor in the synthesis of various medications due to its ability to interact with neurotransmitter systems in the brain. Its potential applications include the development of treatments for neurological and psychiatric disorders, leveraging its interaction with brain chemistry to address specific conditions.
Used in Research Industry:
In the research field, 3-(3-Methoxyphenyl)pyrrolidine serves as a valuable compound for studying the effects of pyrrolidine derivatives on neurotransmission and receptor binding. It aids scientists in understanding the mechanisms of action of related compounds and contributes to the discovery of novel therapeutic agents.
Used in Organic Synthesis:
3-(3-Methoxyphenyl)pyrrolidine is also utilized as a building block in the synthesis of novel organic compounds and materials. Its unique structure allows for the creation of new chemical entities with potential applications in various fields, such as materials science, medicinal chemistry, and specialty chemicals.

Upstream product

• 626-20-0 3-methoxystyrene 
• 1056971-34-6 N-benzyl-3-(3-methoxyphenyl)pyrrolidine 
• 38175-34-7 4-(3-methoxyphenyl)pyrrolidin-2-one 
• 591-31-1 3-methoxy-benzaldehyde 
• 372944-87-1 methyl 3-(3-methoxyphenyl)-4-nitrobutanoate 
• 38693-90-2 trans-3-(3-methoxyphenyl)acrylic acid methyl ester 

Downstream Products

• 129084-17-9 1-[2-(diphenylmethoxy) ethyl]-3-(3-methoxyphenyl)pyrrolidine 

Relevant academic research and scientific papers

Preparation method of tetrahydropyrrole compound

The invention discloses a preparation method of a tetrahydropyrrole compound. According to the preparation method, common easily available 3-methoxybenzaldehyde is used as an initial raw material, a compound 002 is obtained through a Wttig reaction, a cyc

Tetrahydropyrrole compound, preparation method, pharmaceutical composition and application thereof

The invention discloses a tetrahydropyrrole compound and a preparation method, a pharmaceutical composition and application thereof. The tetrahydropyrrole compound of the invention is as shown in thegeneral formula (I). The tetrahydropyrrole compound of the invention has an excellent inhibitory effect on the positive symptom of schizophrenia, and has equivalent or stronger efficacy in comparisonwith the positive medicine olanzapine. In addition, the compound of the invention has a dual inhibitory effect on a D2 receptor and a DAT receptor, can effectively treat schizophrenia and improve negative symptoms and cognitive functions, and helps reduce side-effect of centrum and secretion of lactogen.

The Titanium-Mediated Double Reductive Cleavage of Cyclic Sulfonamides for the Synthesis of Aryl Pyrrolidines

Reduction of a range of benzo-fused cyclic sulfonamides has been accomplished using low-valent titanium. This operationally simple method generates the corresponding aryl-substituted cyclic amines, typically, with good conversion. Notably, unlike our previous Li-NH3-based method, loss of heteroatom-based substituents (X) on the aromatic ring does not readily occur, and the robustness of this method was demonstrated with a synthesis of the Sceletium alkaloid mesembrane.

Synthesis of 3-(3-hydroxyphenyl)pyrrolidine dopamine D3 receptor ligands with extended functionality for probing the secondary binding pocket

A series of 3-(3-hydroxyphenyl)pyrrolidine analogues which incorporate N-alkyl groups and N-butylamide-linked benzamide functionality have been synthesized and their in vitro binding affinities at human dopamine receptors have been evaluated. Our ligand design strategy was to take the 3-(3-hydroxyphenyl)pyrrolidine scaffold and extend functionality from the orthosteric binding site to the secondary binding pocket for enhancing affinity and selectivity for the D3 receptor. The N-alkyl analogues constitute a homologous series from N-pentyl to N-decyl to probe the length/bulk tolerance of the secondary binding pocket of the D3 receptor. Enantiomeric 3-(3-hydroxyphenyl)pyrrolidine analogues were also prepared in order to test the chirality preference of the orthosteric binding site for this scaffold. Benzamide analogues were prepared to enhance affinity and/or selectivity based upon the results of the homologous series.

Oximes and hydrazones that are useful in treating sexual dysfunction

The present invention relates to oximes and hydrazones of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.